ERBB2 and breast carcinoma: MGAH22 demonstrated ADCC activity with EC50 values lower than those of RES120 against breast and non-breast cancer cell lines encompassing a wide range of surface HER2 expression with effector cells (PBMCs) from CD16A F/F or V/F donors (Figure 3f-m).